(IN BRIEF) IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing from the European Commission’s InvestEU programme. The financing, structured in three committed tranches of up to €37.5 … Read the full press release
Posted in Banks, Denmark, European Union, Financial, Healthcare, Investment, Luxembourg, Pharma & Biotech, Technology
Tagged Amy Sullivan, cancer vaccine, clinical development, EIB, European Commission, immunotherapeutic, InvestEU, IO Biotech, IO102-IO103, Ioannis Tsakiris, market launch, med-tech, melanoma, oncology, Pharmaceutical, regulatory approval, T-Win® platform, venture debt
(IN BRIEF) Researchers from The Institute of Cancer Research, London, and Barts Cancer Institute have discovered how the extracellular matrix (ECM) surrounding tumours influences cancer cells to become aggressive and spread throughout the body. Their study, published in Nature Communications, … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged Barts Cancer Institute, breast cancer, cancer metastasis, cancer research, Cancer Therapies, cancer treatment, early cancer detection, ECM, extracellular matrix, ICR, lysyl oxidase, melanoma, metastasis, metastasis prevention, Nature Communications, tumor behavior, tumor biology
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Switzerland
Tagged BRAFmutation, dabrafenib, inhibitor, Mekinist®, melanoma, Novartis, Tafinlar®, trametinib, tumor
BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Sweden
Tagged BRIM8, melanoma, phase III BRIM8 study, Roche, Sandra Horning MD
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated significant improvement in health-related quality of life vs vemurafenib monotherapy in this … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?